These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15370250)

  • 1. Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression.
    Dimopoulos MA; Alexanian R; Gika D; Anagnostopoulos A; Zervas C; Zomas A; Kyrtsonis MC; Anagnostopoulos N; Pangalis GA; Weber DM
    Leuk Lymphoma; 2004 Oct; 45(10):2057-61. PubMed ID: 15370250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia.
    Dimopoulos MA; Anagnostopoulos A; Zervas C; Kyrtsonis MC; Zomas A; Bourantas C; Anagnostopoulos N; Pangalis G
    Clin Lymphoma; 2005 Mar; 5(4):270-2. PubMed ID: 15794863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Waldenström's macroglobulinemia with rituximab.
    Dimopoulos MA; Zervas C; Zomas A; Kiamouris C; Viniou NA; Grigoraki V; Karkantaris C; Mitsouli C; Gika D; Christakis J; Anagnostopoulos N
    J Clin Oncol; 2002 May; 20(9):2327-33. PubMed ID: 11981004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.
    Dimopoulos MA; Zervas C; Zomas A; Hamilos G; Gika D; Efstathiou E; Panayiotidis P; Vervessou E; Anagnostopoulos N; Christakis J
    Clin Lymphoma; 2002 Dec; 3(3):163-6. PubMed ID: 12521393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
    Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity.
    Byrd JC; White CA; Link B; Lucas MS; Velasquez WS; Rosenberg J; Grillo-López AJ
    Ann Oncol; 1999 Dec; 10(12):1525-7. PubMed ID: 10643548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended rituximab therapy in Waldenström's macroglobulinemia.
    Treon SP; Emmanouilides C; Kimby E; Kelliher A; Preffer F; Branagan AR; Anderson KC; Frankel SR;
    Ann Oncol; 2005 Jan; 16(1):132-8. PubMed ID: 15598950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of rituximab on a patient with Waldenström's macroglobulinaemia with deletion 13q14.
    Mori A; Tamaru J; Kondo H
    Eur J Haematol; 2002; 69(5-6):321-3. PubMed ID: 12460239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab, Cyclophosphamide, Dexamethasone (RCD) regimen induces cure in WSU-WM xenograft model and a partial remission in previously treated Waldenstrom's macroglobulinemia patient.
    Mohammad RM; Aboukameel A; Nabha S; Ibrahim D; Al-Katib A
    J Drug Target; 2002 Aug; 10(5):405-10. PubMed ID: 12442811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
    Tam CS; Wolf MM; Westerman D; Januszewicz EH; Prince HM; Seymour JF
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):136-9. PubMed ID: 16231852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia.
    Treon SP; Hanzis C; Tripsas C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):133-5. PubMed ID: 21454214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
    Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
    J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98).
    Gertz MA; Rue M; Blood E; Kaminer LS; Vesole DH; Greipp PR
    Leuk Lymphoma; 2004 Oct; 45(10):2047-55. PubMed ID: 15370249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia.
    Herth I; Hensel M; Rieger M; Horstmann K; Hiddemann W; Dreyling M; Koniczek S; Witzens-Harig M; Ho AD
    Leuk Lymphoma; 2015 Jan; 56(1):97-102. PubMed ID: 24724778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Kanan S; Sheehy P; Chuma S; Xu L; Cao Y; Yang G; Liu X; Patterson CJ; Warren D; Hunter ZR; Turnbull B; Ghobrial IM; Castillo JJ
    Blood; 2014 Jul; 124(4):503-10. PubMed ID: 24859363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab-based treatments in Waldenström's macroglobulinemia.
    Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
    Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Chu L; Musto P; Baron AD; Nunnink JC; Kash JJ; Terjanian TO; Hyman PM; Nawfel EL; Sharon DJ; Munshi NC; Anderson KC
    Clin Cancer Res; 2009 Jan; 15(1):355-60. PubMed ID: 19118065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
    Treon SP; Hansen M; Branagan AR; Verselis S; Emmanouilides C; Kimby E; Frankel SR; Touroutoglou N; Turnbull B; Anderson KC; Maloney DG; Fox EA
    J Clin Oncol; 2005 Jan; 23(3):474-81. PubMed ID: 15659493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].
    Yoshimi A; Arai S; Iijima K; Iki S; Usuki K; Urabe A
    Rinsho Ketsueki; 2005 Oct; 46(10):1109-13. PubMed ID: 16440772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.
    Liberato B; Riethmuller A; Comenzo RL; Lis E; Raizer JJ
    J Neurooncol; 2003 Jun; 63(2):207-11. PubMed ID: 12825826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.